Clinical Trials Browser

Lymphoma, B-Cell × pembrolizumab × 1 year × Clear all

NCT06484920 2026-02-10

A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL

Phase 2 Recruiting

Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03598608 2026-02-05

MK-4280-003

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT06242834 2026-01-14

Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Phase 2 Recruiting

Lymphoma, B-Cell

NCT03150329 2025-09-03

Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Phase 1 Active not recruiting

52 enrolled 13 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT05507541 2025-08-29

TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT03995147 2025-06-08

Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell Lymphoma

Phase 2 Active not recruiting

Lymphoma, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT04317066 2025-04-06

KEYNOTE-A33

Phase 1 Completed

7 enrolled 13 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lymphoma, B-Cell